$0.314
+0.040 (+12.63%)收盤時
LSH 資訊
LSH 事件
Lakeside Holding Files $120M Mixed Securities Shelf
Lakeside Holding files $120M mixed securities shelf
Lakeside Holding secures new distribution agreements with Kelun Pharmaceutical
Lakeside Holding is pleased to announce that its wholly owned subsidiary, Hupan Pharmaceutical Co., has entered into two distribution agreements with Hubei Kelun Pharmaceutical Trading Co., Ltd., a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., a publicly traded company on the Shenzhen Stock Exchange, principally engaged in the research and development, manufacture and distribution of pharmaceutical products. Under the agreements, Hupan Pharmaceutical will distribute basic large-volume parenteral solutions, along with related medical products and equipment, to healthcare institutions across China. The agreements, effective from January 1, 2025, to December 31, 2025, further expand Hupan Pharmaceutical's portfolio of medical distribution clients.
Lakeside Holding partners with Huiyu Pharma in oncology drug distribution
Lakeside Holding announced that its recent acquisition in China, Hupan Pharmaceutical, has entered into a strategic distribution agreement with Sichuan Huiyu Pharmaceutical, a company dealing in oncology and immune-related therapies, listed on the Shanghai Stock Exchange. Hupan Pharmaceutical will distribute Huiyu Pharmaceutical's oncology and immunotherapy drugs to hospitals and healthcare institutions to domestic and global markets. Huiyu Pharmaceutical's flagship product, Pemetrexed Disodium for Injection, has received regulatory approvals in major markets, including China, the UK, Germany, and Finland.
Lakeside Holding signs $1.5M sales agreement with Sinopharm Group subsidiary
Lakeside Holding subsidiary Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine, a subsidiary of Sinopharm Group. The agreement, valued at approximately $1.5M, is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride. This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services.
Lakeside Holding to acquire Hupan Pharmaceutical for $600,000
Lakeside Holding is pleased to announce that through its wholly-owned subsidiary, Sichuan Hupan Jincheng Enterprise Management Co., has entered into an equity transfer agreement to acquire Hupan Pharmaceutical, gaining entry into the medical logistics sector. The acquisition, valued at $0.6M, is anticipated to deliver approximately $7M of annual revenues to Lakeside. Founded in May 2024 and headquartered in Wuhan, Hupan Pharmaceutical is a comprehensive pharmaceutical distribution and supply chain service provider with verticals in brand promotion and healthcare technology support. Hupan Pharmaceutical is licensed for drug wholesale, retail, and third-class medical device distribution in China, with recent expansion to include refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。